# Wellnara Post-marketing Surveillance in Japan

> **NCT01401114** · — · COMPLETED · sponsor: **Bayer** · enrollment: 411 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** E2/LNG oral (Wellnara, BAY86-5029)

## Key facts

- **NCT ID:** NCT01401114
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401114, "Wellnara Post-marketing Surveillance in Japan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01401114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*